Welcome to the HCV Advocate’s
2010 AASLD Conference coverage. In an
effort to best serve our readership, we are concentrating on the current and
future medications to treat hepatitis C.
While attending the conference, we will update any abstracts that we personally cover at the conference. The
updated abstracts will be marked with the date that they have been updated and
posted. The other abstracts posted to
the web site are HCV-related abstracts posted to www.aasld.org that we have not been able to report on or
update.
To locate specific abstracts
for each medication, click on the links.
Please click here to view our fact sheet on reading and understanding
an abstract.
Thank You,
Alan Franciscus
Editor-in-Chief
Hepatitis C
·
Interferon and
Ribavirin Therapy – New Studies: The
current treatments for hepatitis C, including outcomes, side effects and
treatment of various HCV populations.
·
Direct-Acting
Antiviral Agents (DAA’s): New treatments for hepatitis C that have been studied
in humans, and various drugs that are in phase I, II and